Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).
I'm PortAI, I can summarize articles.
Celltrion, Inc. has signed an agreement to acquire a Biopharmaceutical Manufacturing Facility in the U.S. from Eli Lilly and Company for $330 million. The acquisition, proposed on July 29, 2025, involves an investment of 700 billion won (approximately $503 million), with potential additional investments based on market demand. Due diligence will be conducted before finalizing the agreement, with the transaction expected to close by the end of 2025. The acquisition was completed on January 2, 2026.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments